388 related articles for article (PubMed ID: 34724172)
1. Phase 3, Randomized, 20-Month Study of the Efficacy and Safety of Bimatoprost Implant in Patients with Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 2).
Bacharach J; Tatham A; Ferguson G; Belalcázar S; Thieme H; Goodkin ML; Chen MY; Guo Q; Liu J; Robinson MR; Bejanian M; Wirta DL;
Drugs; 2021 Nov; 81(17):2017-2033. PubMed ID: 34724172
[TBL] [Abstract][Full Text] [Related]
2. Phase 3, Randomized, 20-Month Study of Bimatoprost Implant in Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 1).
Medeiros FA; Walters TR; Kolko M; Coote M; Bejanian M; Goodkin ML; Guo Q; Zhang J; Robinson MR; Weinreb RN;
Ophthalmology; 2020 Dec; 127(12):1627-1641. PubMed ID: 32544560
[TBL] [Abstract][Full Text] [Related]
3. Six-Month Intraocular Pressure Reduction with a Topical Bimatoprost Ocular Insert: Results of a Phase II Randomized Controlled Study.
Brandt JD; Sall K; DuBiner H; Benza R; Alster Y; Walker G; Semba CP;
Ophthalmology; 2016 Aug; 123(8):1685-1694. PubMed ID: 27157843
[TBL] [Abstract][Full Text] [Related]
4. Fixed-combination Bimatoprost/Brimonidine/Timolol in Glaucoma: A Randomized, Masked, Controlled, Phase III Study Conducted in Brazil
Belfort R; Paula JS; Lopes Silva MJ; Della Paolera M; Kim T; Chen MY; Goodkin ML
Clin Ther; 2020 Feb; 42(2):263-275. PubMed ID: 32089329
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of the Travoprost Intraocular Implant in Reducing Topical IOP-Lowering Medication Burden in Patients with Open-Angle Glaucoma or Ocular Hypertension.
Berdahl JP; Sarkisian SR; Ang RE; Doan LV; Kothe AC; Usner DW; Katz LJ; Navratil T;
Drugs; 2024 Jan; 84(1):83-97. PubMed ID: 38060092
[TBL] [Abstract][Full Text] [Related]
6. MERCURY-3: a randomized comparison of netarsudil/latanoprost and bimatoprost/timolol in open-angle glaucoma and ocular hypertension.
Stalmans I; Lim KS; Oddone F; Fichtl M; Belda JI; Hommer A; Laganovska G; Schweitzer C; Voykov B; Zarnowski T; Holló G
Graefes Arch Clin Exp Ophthalmol; 2024 Jan; 262(1):179-190. PubMed ID: 37615697
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of fixed-combination bimatoprost/timolol versus fixed-combination dorzolamide/brimonidine/timolol in patients with primary open-angle glaucoma or ocular hypertension: a multicenter, prospective, crossover study.
García-López A; Paczka JA; Jiménez-Román J; Hartleben C
BMC Ophthalmol; 2014 Dec; 14():161. PubMed ID: 25527295
[TBL] [Abstract][Full Text] [Related]
8. Bimatoprost 0.03%/timolol 0.5% preservative-free ophthalmic solution versus bimatoprost 0.03%/timolol 0.5% ophthalmic solution (Ganfort) for glaucoma or ocular hypertension: a 12-week randomised controlled trial.
Goldberg I; Gil Pina R; Lanzagorta-Aresti A; Schiffman RM; Liu C; Bejanian M
Br J Ophthalmol; 2014 Jul; 98(7):926-31. PubMed ID: 24667994
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of bimatoprost/timolol fixed combination in Chinese patients with open-angle glaucoma or ocular hypertension.
Ling Z; Zhang M; Hu Y; Yin Z; Xing Y; Fang A; Ye J; Chen X; Liu D; Wang Y; Sun W; Dong Y; Sun X
Chin Med J (Engl); 2014; 127(5):905-10. PubMed ID: 24571886
[TBL] [Abstract][Full Text] [Related]
10. Effects of Topical Bimatoprost 0.01% and Timolol 0.5% on Circadian IOP, Blood Pressure and Perfusion Pressure in Patients with Glaucoma or Ocular Hypertension: A Randomized, Double Masked, Placebo-Controlled Clinical Trial.
Oddone F; Rossetti L; Tanga L; Berardo F; Ferrazza M; Michelessi M; Roberti G; Manni G; Centofanti M
PLoS One; 2015; 10(10):e0140601. PubMed ID: 26484767
[TBL] [Abstract][Full Text] [Related]
11. Single Administration of Intracameral Bimatoprost Implant 10 µg in Patients with Open-Angle Glaucoma or Ocular Hypertension.
Medeiros FA; Sheybani A; Shah MM; Rivas M; Bai Z; Werts E; Ahmed IIK; Craven ER
Ophthalmol Ther; 2022 Aug; 11(4):1517-1537. PubMed ID: 35643967
[TBL] [Abstract][Full Text] [Related]
12. Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment.
Oddone F; Kirwan J; Lopez-Lopez F; Zimina M; Fassari C; Holló G;
Adv Ther; 2022 Aug; 39(8):3501-3521. PubMed ID: 35524840
[TBL] [Abstract][Full Text] [Related]
13. Changes in ocular signs and symptoms in patients switching from bimatoprost-timolol to tafluprost-timolol eye drops: an open-label phase IV study.
Bourne RRA; Kaarniranta K; Lorenz K; Traverso CE; Vuorinen J; Ropo A
BMJ Open; 2019 Apr; 9(4):e024129. PubMed ID: 30944129
[TBL] [Abstract][Full Text] [Related]
14. 24-Month Phase I/II Clinical Trial of Bimatoprost Sustained-Release Implant (Bimatoprost SR) in Glaucoma Patients.
Craven ER; Walters T; Christie WC; Day DG; Lewis RA; Goodkin ML; Chen M; Wangsadipura V; Robinson MR; Bejanian M;
Drugs; 2020 Feb; 80(2):167-179. PubMed ID: 31884564
[TBL] [Abstract][Full Text] [Related]
15. A 3-month randomized controlled trial of bimatoprost (LUMIGAN) versus combined timolol and dorzolamide (Cosopt) in patients with glaucoma or ocular hypertension.
Coleman AL; Lerner F; Bernstein P; Whitcup SM
Ophthalmology; 2003 Dec; 110(12):2362-8. PubMed ID: 14644719
[TBL] [Abstract][Full Text] [Related]
16. Topical bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension.
Easthope SE; Perry CM
Drugs Aging; 2002; 19(3):231-48. PubMed ID: 12027782
[TBL] [Abstract][Full Text] [Related]
17. Tolerability and efficacy of bimatoprost 0.01 % in patients with open-angle glaucoma or ocular hypertension evaluated in the Taiwanese clinical setting: the Asia Pacific Patterns from Early Access of Lumigan 0.01 % (APPEAL Taiwan) study.
Chen YY; Wang TH; Liu C; Wu KY; Chiu SL; Simonyi S; Lu DW
BMC Ophthalmol; 2016 Sep; 16(1):162. PubMed ID: 27633513
[TBL] [Abstract][Full Text] [Related]
18. Single Administration of Bimatoprost Implant: Effects on 24-Hour Intraocular Pressure and 1-Year Outcomes.
Weinreb RN; Christie WC; Medeiros FA; Craven ER; Kim K; Nguyen A; Bejanian M; Wirta DL
Ophthalmol Glaucoma; 2023; 6(6):599-608. PubMed ID: 37343625
[TBL] [Abstract][Full Text] [Related]
19. Latanoprostene Bunod 0.024% versus Timolol Maleate 0.5% in Subjects with Open-Angle Glaucoma or Ocular Hypertension: The APOLLO Study.
Weinreb RN; Scassellati Sforzolini B; Vittitow J; Liebmann J
Ophthalmology; 2016 May; 123(5):965-73. PubMed ID: 26875002
[TBL] [Abstract][Full Text] [Related]
20. Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP : a 3-month clinical trial.
Brandt JD; VanDenburgh AM; Chen K; Whitcup SM;
Ophthalmology; 2001 Jun; 108(6):1023-31; discussion 1032. PubMed ID: 11382623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
